Shawn Olsson serves as Chief Commercial Officer at LENZ Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing innovative treatments for presbyopia. With more than 25 years of experience in the pharmaceutical industry, Shawn has built a distinguished career specializing in ophthalmology commercial strategy, market access, and product launches. He began his journey at Allergan, where he played a pivotal role in the successful commercialization of blockbuster ophthalmic products, establishing a foundation in data-driven marketing and sales leadership. Prior to joining LENZ, Shawn held the position of Vice President of U.S. Marketing for Surgical and Pharma at Bausch + Lomb, overseeing a portfolio that included key brands such as Lotemax SM, Vyzulta, and Prolensa. Under his leadership, these products achieved substantial market share growth and revenue milestones, demonstrating his expertise in navigating competitive landscapes and optimizing go-to-market strategies. His earlier roles at Sun Ophthalmics and Inspire Pharmaceuticals further honed his skills in launching specialty eye care therapies and building high-performing commercial teams. At LENZ Therapeutics, Shawn leads the commercial organization, driving the strategy and execution for the upcoming launch of LNZ100 (aceclidine eye solution), a potential first-in-category presbyopia treatment. His proven track record positions him to guide the company through pivotal commercialization phases, leveraging deep industry insights to deliver transformative solutions for the millions affected by age-related near vision loss.